%0 Journal Article
%A Noriega, Víctor
%A Martínez-Laperche, Carolina
%A Buces, Elena
%A Pion, Marjorie
%A Sánchez-Hernández, Noemí
%A Martín-Antonio, Beatriz
%A Guillem, Vicent
%A Bosch-Vizcaya, Anna
%A Bento, Leyre
%A González-Rivera, Milagros
%A Balsalobre, Pascual
%A Kwon, Mi
%A Serrano, David
%A Gayoso, Jorge
%A de la Cámara, Rafael
%A Brunet, Salut
%A Rojas-Contreras, Rafael
%A Nieto, José B
%A Martínez, Carmen
%A Gónzalez, Marcos
%A Espigado, Ildefonso
%A Vallejo, Juan C
%A Sampol, Antonia
%A Jiménez-Velasco, Antonio
%A Urbano-Ispizua, Alvaro
%A Solano, Carlos
%A Gallardo, David
%A Díez-Martín, José L
%A Buño, Ismael
%T The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation.
%D 2015
%U http://hdl.handle.net/10668/2284
%X The FOXP3 gene encodes for a protein (Foxp3) involved in the development and functional activity of regulatory T cells (CD4+/CD25+/Foxp3+), which exert regulatory and suppressive roles over the immune system. After allogeneic stem cell transplantation, regulatory T cells are known to mitigate graft versus host disease while probably maintaining a graft versus leukemia effect. Short alleles (≤(GT)15) for the (GT)n polymorphism in the promoter/enhancer of FOXP3 are associated with a higher expression of FOXP3, and hypothetically with an increase of regulatory T cell activity. This polymorphism has been related to the development of auto- or alloimmune conditions including type 1 diabetes or graft rejection in renal transplant recipients. However, its impact in the allo-transplant setting has not been analyzed. In the present study, which includes 252 myeloablative HLA-identical allo-transplants, multivariate analysis revealed a lower incidence of grade III-IV acute graft versus host disease (GVHD) in patients transplanted from donors harboring short alleles (OR = 0.26, CI 0.08-0.82, p = 0.021); without affecting chronic GVHD or graft versus leukemia effect, since cumulative incidence of relapse, event free survival and overall survival rates are similar in both groups of patients.
%K Anciano
%K Femenino
%K Adulto
%K Factores de transcripción en cabeza de tenedor
%K Estudios de asociación genética
%K Genotipo
%K Enfermedad injerto contra huésped
%K Efecto injerto contra leucemia
%K Trasplante de células madre hematopoyéticas
%K Humanos
%K Masculino
%K Mediana edad
%K Polimorfismo genético
%K Regiones promotoras genéticas
%K Análisis de supervivencia
%K Donantes de tejidos
%K Trasplante homólogo
%~